MX2010006243A - Moduladores de gamma secretasa. - Google Patents

Moduladores de gamma secretasa.

Info

Publication number
MX2010006243A
MX2010006243A MX2010006243A MX2010006243A MX2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A MX 2010006243 A MX2010006243 A MX 2010006243A
Authority
MX
Mexico
Prior art keywords
gamma secretase
formula
secretase modulators
compounds
methods
Prior art date
Application number
MX2010006243A
Other languages
English (en)
Inventor
John Clader
William J Greenlee
Zhaoning Zhu
Zhiqiang Zhao
Xianhai Huang
Dmitri Pissarnitski
Anandan Palani
Xiaohong Zhu
Jun Qin
Robert G Aslanian
Mihirbaran Mandal
Thomas Bara
Chad E Bennett
Hubert Josien
Pawan Dhondi
Wei Zhou
Troy Mccracken
Duane Burnett
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of MX2010006243A publication Critical patent/MX2010006243A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Está invención provee compuestos que son moduladores de gamma secretasa; los compuestos de la fórmula I (ver fórmula (I)) en donde R2 es un anillo bicíclico condensado de la fórmula (II) (ver fórmula (I)) se exponen también métodos de modular la actividad de gamma secretasa y métodos de tratar la enfermedad de Alzheimer usando los compuestos de la fórmula (I).
MX2010006243A 2007-12-06 2008-12-04 Moduladores de gamma secretasa. MX2010006243A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US99283907P 2007-12-06 2007-12-06
PCT/US2008/085515 WO2009073777A1 (en) 2007-12-06 2008-12-04 Gamma secretase modulators

Publications (1)

Publication Number Publication Date
MX2010006243A true MX2010006243A (es) 2010-08-31

Family

ID=40351934

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010006243A MX2010006243A (es) 2007-12-06 2008-12-04 Moduladores de gamma secretasa.

Country Status (13)

Country Link
US (1) US8450343B2 (es)
EP (1) EP2229381A1 (es)
JP (1) JP2011506335A (es)
KR (1) KR20100094554A (es)
CN (1) CN101939315A (es)
AR (1) AR069635A1 (es)
AU (1) AU2008333865A1 (es)
CA (1) CA2707712A1 (es)
IL (1) IL206172A0 (es)
MX (1) MX2010006243A (es)
PE (1) PE20091095A1 (es)
TW (1) TW200930366A (es)
WO (1) WO2009073777A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010002098A (es) 2007-08-31 2010-03-30 Eisai R&D Man Co Ltd Compuesto policiclico.
BRPI0921317A2 (pt) 2008-11-06 2017-06-06 Astrazeneca Ab composto, composição farmacêutica, e, método para tratar ou prevenir uma patologia relacionada com abeta em um mamífero
PA8854101A1 (es) 2008-12-18 2010-07-27 Ortho Mcneil Janssen Pharm Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa
AP2011005779A0 (en) 2009-02-06 2011-08-31 Ortho Mcneil Janssen Pharm Novel susbstituted bicyclic heterocyclic compoundsas gamma secretase modulators.
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
CN102333777B (zh) 2009-02-26 2014-06-25 卫材R&D管理有限公司 含氮的稠合杂环化合物及其作为β淀粉样蛋白生成抑制剂的用途
NZ596843A (en) 2009-05-07 2012-12-21 Janssen Pharmaceuticals Inc Novel substituted indazole and aza-indazole derivatives as gamma secretase modulators
WO2010140339A1 (ja) * 2009-06-01 2010-12-09 武田薬品工業株式会社 複素環化合物
WO2011007756A1 (ja) 2009-07-13 2011-01-20 武田薬品工業株式会社 複素環化合物及びその用途
EP2454239B1 (en) * 2009-07-15 2014-08-13 Janssen Pharmaceuticals Inc. Substituted triazole and imidazole derivatives as gamma secretase modulators
US8637525B2 (en) 2009-07-31 2014-01-28 Bristol-Myers Squibb Company Compounds for the reduction of beta-amyloid production
TWI468402B (zh) * 2009-07-31 2015-01-11 必治妥美雅史谷比公司 降低β－類澱粉生成之化合物
BR112012017310A2 (pt) 2010-01-15 2016-04-19 Janssen Pharmaceuticals Inc derivados de triazol substituídos como moduladores de gama secretase
TW201206946A (en) * 2010-07-15 2012-02-16 Bristol Myers Squibb Co Compounds for the reduction of beta-amyloid production
US9272966B2 (en) * 2010-07-22 2016-03-01 Kowa Company, Ltd. Method for preparing optically active 1-bromo-1[3,5-bis(trifluoromethyl)phenyl]ethane
EP2611805A1 (en) * 2010-09-02 2013-07-10 Takeda Pharmaceutical Company Limited Fused triazoles for the treatment or prophylaxis of mild cognitive impairment
MX2013007938A (es) 2011-01-07 2013-11-01 Taiho Pharmaceutical Co Ltd Compuesto biciclico novedoso o sal del mismo.
WO2012093707A1 (ja) * 2011-01-07 2012-07-12 大鵬薬品工業株式会社 新規インドール、インダゾール誘導体又はその塩
KR20140047032A (ko) 2011-03-24 2014-04-21 얀센 파마슈티칼즈, 인코포레이티드 감마 세크레타제 조정제로서의 신규 치환 트리아졸릴 피페라진 및 트리아졸릴 피페리딘 유도체
IN2014MN00258A (es) * 2011-07-15 2015-09-25 Janssen Pharmaceuticals Inc
MX339302B (es) 2011-09-15 2016-05-19 Novartis Ag 3-(quinolin-6-il-tio)-[1,2,4]-triazolo-[4,3-a]-piridinas 6-sustituidas como cinasas de tirosina.
US9096582B2 (en) 2011-10-31 2015-08-04 Merck Sharp & Dohme Corp Gamma secretase modulators
AU2013261023B2 (en) 2012-05-16 2016-11-24 Cellzome Limited Substituted 3, 4 - dihydro - 2H - pyrido [1, 2 -a] pyrazine - 1, 6 - dione derivatives useful for the treatment of (inter alia) Alzheimer's disease
EP2687528A1 (en) * 2012-07-17 2014-01-22 Ares Trading S.A. Fused triazole derivatives as gamma secretase modulators
RU2652117C2 (ru) * 2012-10-31 2018-04-25 Раквалиа Фарма Инк. Производные пиразолопиридина в качестве блокаторов ttx-s
MX2015005812A (es) 2012-11-08 2015-09-23 Pfizer Compuestos heteroaromaticos y su uso como ligandos de dopamina d1.
AU2013343105B2 (en) 2012-11-08 2016-04-14 Pfizer Inc. Heteroaromatic compounds as dopamine D1 ligands
CA2889249C (en) 2012-12-20 2021-02-16 Francois Paul Bischoff Tricyclic 3,4-dihydro-2h-pyrido[1,2-a]pyrazine-1,6-dione derivatives as gamma secretase modulators
EP2945944B1 (en) 2013-01-17 2016-11-09 Janssen Pharmaceutica, N.V. Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
CN105940001B (zh) * 2013-12-12 2018-02-06 株式会社钟根堂 作为选择性组蛋白脱乙酰酶(hdac)抑制剂的新型氮杂吲哚衍生物及包含其的药物组合物
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
JO3637B1 (ar) 2015-04-28 2020-08-27 Janssen Sciences Ireland Uc مركبات بيرازولو- وترايازولو- بيريميدين مضادة للفيروسات rsv
AU2016255431B2 (en) * 2015-04-29 2020-05-07 Janssen Pharmaceutica Nv Imidazopyrazines and pyrazolopyrimidines and their use as AMPA receptor modulators
CN107835814B (zh) 2015-04-29 2021-07-23 詹森药业有限公司 氮杂苯并咪唑及其作为ampa受体调节剂的用途
TW201932470A (zh) 2017-11-29 2019-08-16 愛爾蘭商健生科學愛爾蘭無限公司 具有抗ｒｓｖ活性之吡唑并嘧啶
CA3087926A1 (en) 2018-01-31 2019-08-08 Janssen Sciences Ireland Unlimited Company Cycloalkyl substituted pyrazolopyrimidines having activity against rsv
KR20210005569A (ko) 2018-04-23 2021-01-14 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Rsv에 대한 활성을 갖는 헤테로방향족 화합물
US20220048987A1 (en) * 2020-08-13 2022-02-17 The Board Of Trustees Of The Leland Stanford Junior University Method of treatment to prevent or reverse age-associated inflammation, cognitive decline, and neurodegeneration

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5026712A (en) * 1985-06-05 1991-06-25 Schering Ag Novel imidazo[1,5-a]pyridines, useful as cardiovascular and CNS agents
US4937258A (en) * 1989-09-12 1990-06-26 Berlex Laboratories, Inc. Pyrrolo[1,2-c]imidazolone derivatives as PDE inhibitors
WO2004071431A2 (en) 2003-02-05 2004-08-26 Myriad Genetics, Inc. Method and composition for treating neurodegenerative disorders
AU2004247013B2 (en) 2003-05-14 2010-07-08 Neurogenetic Pharmaceuticals, Inc. Compounds and uses thereof in modulating amyloid beta
JP2007528857A (ja) * 2003-07-11 2007-10-18 ミリアド ジェネティクス， インコーポレイテッド アルツハイマー病の処置のための薬学的方法、投与レジメンおよび投薬形態
EP1697369A1 (en) * 2003-12-22 2006-09-06 SB Pharmco Puerto Rico Inc Crf receptor antagonists and methods relating thereto
US20070293538A1 (en) 2004-04-13 2007-12-20 Myriad Genetics, Incorporated Pharmaceutical Composition And Methods For Treating Neurodegenerative Disorders
KR101128065B1 (ko) * 2004-05-26 2012-04-12 에자이 알앤드디 매니지먼트 가부시키가이샤 신나미드 화합물
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy

Also Published As

Publication number Publication date
AU2008333865A2 (en) 2010-07-29
TW200930366A (en) 2009-07-16
US20110015190A1 (en) 2011-01-20
JP2011506335A (ja) 2011-03-03
PE20091095A1 (es) 2009-07-25
KR20100094554A (ko) 2010-08-26
AR069635A1 (es) 2010-02-10
EP2229381A1 (en) 2010-09-22
US8450343B2 (en) 2013-05-28
IL206172A0 (en) 2010-12-30
CA2707712A1 (en) 2009-06-11
WO2009073777A1 (en) 2009-06-11
AU2008333865A1 (en) 2009-06-11
CN101939315A (zh) 2011-01-05

Similar Documents

Publication Publication Date Title
MX2010006243A (es) Moduladores de gamma secretasa.
MX2010002674A (es) Moduladores de gamma secretasa.
MX2010006379A (es) Moduladores de la secretasa gamma.
MX2010005028A (es) Moduladores de gamma secretasa.
MX2010006046A (es) Moduladores de gamma secretasa.
CY1117014T1 (el) Παραγωγο συμπυκνωμενης αμινοδιυδροθιαζινης
MX2010006378A (es) Moduladores de gamma secretasa.
TNSN07028A1 (en) Fused ring heterocycle kinase modulators
DE602005014134D1 (de) Verwendung von eph-rezeptor-inhibitoren zur behandlung neurodegenerativer krankheiten
ZA200608306B (en) Fused ring azadecalin glucocorticoid receptor modulators
HK1146056A1 (en) Substituted n-phenyl-bipyrrolidine ureas and therapeutic use thereof
EA201290323A1 (ru) Селективные модуляторы рецептора сфингозин-1-фосфата и способы хирального синтеза
HK1146053A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
HK1097409A1 (en) Azadecalin glucocorticoid receptor modulators
IN2012DN00869A (es)
HK1146054A1 (en) Substituted n-phenyl-bipyrrolidine carboxamides and therapeutic use thereof
MX2019007104A (es) Derivados de dioxido de 1,4-tiazina y dioxido de 1,2,4-tiadiazina como inhibidores de beta-secretasa y metodos de uso.
MY150210A (en) Substituted n-phenyl-pyrrolidinylmethylpyrrolidine amides and therapeutic use thereof as histamine h3 receptor modulators
MX2019007100A (es) Derivados de tiazina y oxazina biciclicos como inhibidores de beta-secretasa y metodos de uso.
MX2019007102A (es) Derivados de tiazina como inhibidores de beta-secretasa y metodos de uso.
MX2010001501A (es) Moduladores de gamma secretasa.
MX2019007103A (es) Derivados de tiazina condensados con ciclopropilo como inhibidores de beta-secretasa y metodos de uso.
BRPI0817433A2 (pt) Moduladores de gama-secretase piperidinila e piperazinila
WO2010147969A3 (en) Gamma secretase modulators

Legal Events

Date Code Title Description
FA Abandonment or withdrawal